Business Description
Genovis AB
ISIN : SE0002485979
Compare
Compare
Traded in other countries / regions
GENO.Sweden5GV.Germany IPO Date
2018-07-18Description
Genovis AB provides enzymes and technologies for the analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce, and market tools for developing new drugs and diagnostics. Its product line comprises GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company's main product category consists of Enzymes and Antibodies. Geographically its segments include Sweden and the rest of the world.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.96 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.36 | |||||
| Debt-to-EBITDA | 1.45 | |||||
| Interest Coverage | 321.02 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 11.58 | |||||
| Beneish M-Score | -2.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 37.1 | |||||
| 3-Year EBITDA Growth Rate | 89.9 | |||||
| 3-Year EPS without NRI Growth Rate | 92.9 | |||||
| 3-Year Book Growth Rate | 29.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 7.57 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.77 | |||||
| 9-Day RSI | 52.28 | |||||
| 14-Day RSI | 52 | |||||
| 3-1 Month Momentum % | 13.52 | |||||
| 6-1 Month Momentum % | -19.96 | |||||
| 12-1 Month Momentum % | -48.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.97 | |||||
| Quick Ratio | 8.97 | |||||
| Cash Ratio | 7 | |||||
| Days Inventory | 359.62 | |||||
| Days Sales Outstanding | 42.88 | |||||
| Days Payable | 103.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -4.41 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.34 | |||||
| Operating Margin % | 31.92 | |||||
| Net Margin % | 21.51 | |||||
| FCF Margin % | 21.93 | |||||
| ROE % | 13.73 | |||||
| ROA % | 9.26 | |||||
| ROIC % | 16.94 | |||||
| 3-Year ROIIC % | 48.57 | |||||
| ROC (Joel Greenblatt) % | 38.41 | |||||
| ROCE % | 15.54 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 60.24 | |||||
| Forward PE Ratio | 46.98 | |||||
| PE Ratio without NRI | 60.24 | |||||
| Shiller PE Ratio | 709.68 | |||||
| Price-to-Owner-Earnings | 24.37 | |||||
| PEG Ratio | 0.88 | |||||
| PS Ratio | 12.77 | |||||
| PB Ratio | 7.45 | |||||
| Price-to-Tangible-Book | 8.33 | |||||
| Price-to-Free-Cash-Flow | 58.44 | |||||
| Price-to-Operating-Cash-Flow | 58.44 | |||||
| EV-to-EBIT | 37.1 | |||||
| EV-to-EBITDA | 29.5 | |||||
| EV-to-Revenue | 12.48 | |||||
| EV-to-FCF | 55.99 | |||||
| Price-to-GF-Value | 0.5 | |||||
| Price-to-Projected-FCF | 3.28 | |||||
| Price-to-Median-PS-Value | 0.76 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.55 | |||||
| Price-to-Graham-Number | 4.81 | |||||
| Price-to-Net-Current-Asset-Value | 16.65 | |||||
| Price-to-Net-Cash | 30.93 | |||||
| Earnings Yield (Greenblatt) % | 2.7 | |||||
| FCF Yield % | 1.71 | |||||
| Forward Rate of Return (Yacktman) % | 21.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genovis AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 11.489 | ||
| EPS (TTM) (€) | 0.037 | ||
| Beta | 2.26 | ||
| 3-Year Sharpe Ratio | -0.3 | ||
| 3-Year Sortino Ratio | -0.42 | ||
| Volatility % | 75.73 | ||
| 14-Day RSI | 52 | ||
| 14-Day ATR (€) | 0.057191 | ||
| 20-Day SMA (€) | 2.217 | ||
| 12-1 Month Momentum % | -48.38 | ||
| 52-Week Range (€) | 1.61 - 4.795 | ||
| Shares Outstanding (Mil) | 65.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genovis AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genovis AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genovis AB Frequently Asked Questions
What is Genovis AB(FRA:5GV)'s stock price today?
The current price of FRA:5GV is €2.17. The 52 week high of FRA:5GV is €4.80 and 52 week low is €1.61.
When is next earnings date of Genovis AB(FRA:5GV)?
The next earnings date of Genovis AB(FRA:5GV) is 2025-02-14 Est..
Does Genovis AB(FRA:5GV) pay dividends? If so, how much?
Genovis AB(FRA:5GV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers